Initiation Reports


BevCanna - Emerging leader in infused beverage innovations

BevCanna Enterprises Inc (CNSX:BEV) offers investors an early-stage opportunity in the emerging...

on 7/10/19

Enteq Upstream - Knowing the drill

Enteq upstream (LON:NTQ) is a leading supplier of high-end systems and products for measurement...

on 27/9/19

Georgina Energy - upcoming IPO

Georgina Energy is an energy company offering investors exposure to an increasingly...

on 9/9/19

Cora Gold - Refilling the Development Pipeline for Producers in West Africa

Fast-track gold projects are few and far between and projects with relatively low capital...

on 6/8/19



Shield Therapeutics PLC: Hitting its clinical targets

Shield Therapeutics (LON:STX) has reported further data from its non-inferiority AEGIS H2H study...

3 weeks, 3 days ago

Gfinity - Building on leadership in esport

Gfinity (LON:GFIN) is a world leader in the fast-growing market for esports. The company...

3 weeks, 3 days ago

Avacta - Transformational new project

Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in...

on 22/10/19
Basic Materials

Itaconix - Trading update

Itaconix (LON:ITX) has issued a trading update for the financial year to 31 December 2019. The...

on 21/10/19

Analyst interviews

Shield Therapeutics: Analyst discusses further positive data from...

Proactive Research analyst Emma Ulker discusses further positive data which has been released from Shield Therapeutics' (LON:STX) non-inferiority AEGIS H2H study. It pitted Shield's oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) against intravenous ferric carboxymaltose...

3 weeks, 1 day ago